TY - JOUR
T1 - Disability in multiple sclerosis is related to thalamic connectivity and cortical network atrophy
AU - Schoonheim, Menno M.
AU - Pinter, Daniela
AU - Prouskas, Stefanos E.
AU - Broeders, Tommy A.
AU - Pirpamer, Lukas
AU - Khalil, Michael
AU - Ropele, Stefan
AU - Uitdehaag, Bernard M.J.
AU - Barkhof, Frederik
AU - Enzinger, Christian
AU - Geurts, Jeroen J.G.
N1 - Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This project was supported by the Dutch MS research foundation, grant numbers 13820 and 14-358e. F.B. is supported by the NIHR Biomedical Research Centre at UCLH. This work originated from the VU University Medical Center (De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands) and Medical University of Graz, Department of Neurology, Auenbruggerplatz 22, 8036 Graz, Austria.
Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This project was supported by the Dutch MS research foundation, grant numbers 13820 and 14-358e. F.B. is supported by the NIHR Biomedical Research Centre at UCLH. This work originated from the VU University Medical Center (De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands) and Medical University of Graz, Department of Neurology, Auenbruggerplatz 22, 8036 Graz, Austria.
Funding Information:
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: D.P. has received funding for travel from Merck, Genzyme/Sanofi-Aventis and Biogen, as well as speaking honoraria from Biogen and Merck. M.K. has received funding for travel and speaker honoraria from Bayer Schering Pharma, Novartis Genzyme, Merck Serono, Biogen Idec and Teva Pharmaceutical Industries Ltd. and a research grant from Teva Pharmaceutical Industries Ltd. C.E. received funding for travelling and speaker honoraria from Biogen Idec, Bayer Schering Pharma, Merck Serono, Novartis, Genzyme and Teva Pharmaceutical Industries Ltd./Sanofi-Aventis, Shire; also received research support from Merck Serono, Biogen Idec and Teva Pharmaceutical Industries Ltd./Sanofi-Aventis; and serves on scientific advisory boards for Bayer Schering Pharma, Biogen Idec, Merck Serono, Novartis, Genzyme, Roche and Teva Pharmaceutical Industries Ltd./Sanofi-Aventis. M.M.S. serves on the editorial board of Frontiers in Neurology, receives research support from the Dutch MS Research Foundation and has served as a consultant for or received research support from Biogen, Celgene, Genzyme, MedDay and Merck. S.E.P. is supported by the Dutch MS Research Foundation, grant number 14-358e. B.M.J.U. reports personal fees from Genzyme, Biogen Idec, TEVA, Merck Serono and Roche, outside the submitted work. F.B. is supported by the NIHR Biomedical Research Centre at UCLH and reports grants and personal fees from Roche, Biogen Idec, Novartis, Merck Serono, TEVA, IXICO, grants and other support from Biogen Idec, Novartis, GE Healthcare and Merck Serono. J.J.G.G. is an editor of Multiple Sclerosis Journal. He serves on the editorial boards of Neurology and Frontiers in Neurology and is president of the Netherlands organization for health research and innovation. He has served as a consultant for or received research support from Biogen, Celgene, Genzyme, MedDay, Merck, Novartis and Teva. All other authors declare no conflicts of interest.
Publisher Copyright:
© The Author(s), 2021.
PY - 2022/1
Y1 - 2022/1
N2 - Background: Thalamic atrophy is proposed to be a major predictor of disability progression in multiple sclerosis (MS), while thalamic function remains understudied. Objectives: To study how thalamic functional connectivity (FC) is related to disability and thalamic or cortical network atrophy in two large MS cohorts. Methods: Structural and resting-state functional magnetic resonance imaging (fMRI) was obtained in 673 subjects from Amsterdam (MS: N = 332, healthy controls (HC): N = 96) and Graz (MS: N = 180, HC: N = 65) with comparable protocols, including disability measurements in MS (Expanded Disability Status Scale, EDSS). Atrophy was measured for the thalamus and seven well-recognized resting-state networks. Static and dynamic thalamic FC with these networks was correlated with disability. Significant correlates were included in a backward multivariate regression model. Results: Disability was most strongly related (adjusted R
2 = 0.57, p < 0.001) to higher age, a progressive phenotype, thalamic atrophy and increased static thalamic FC with the sensorimotor network (SMN). Static thalamus–SMN FC was significantly higher in patients with high disability (EDSS ⩾ 4) and related to network atrophy but not thalamic atrophy or lesion volumes. Conclusion: The severity of disability in MS was related to increased static thalamic FC with the SMN. Thalamic FC changes were only related to cortical network atrophy, but not to thalamic atrophy.
AB - Background: Thalamic atrophy is proposed to be a major predictor of disability progression in multiple sclerosis (MS), while thalamic function remains understudied. Objectives: To study how thalamic functional connectivity (FC) is related to disability and thalamic or cortical network atrophy in two large MS cohorts. Methods: Structural and resting-state functional magnetic resonance imaging (fMRI) was obtained in 673 subjects from Amsterdam (MS: N = 332, healthy controls (HC): N = 96) and Graz (MS: N = 180, HC: N = 65) with comparable protocols, including disability measurements in MS (Expanded Disability Status Scale, EDSS). Atrophy was measured for the thalamus and seven well-recognized resting-state networks. Static and dynamic thalamic FC with these networks was correlated with disability. Significant correlates were included in a backward multivariate regression model. Results: Disability was most strongly related (adjusted R
2 = 0.57, p < 0.001) to higher age, a progressive phenotype, thalamic atrophy and increased static thalamic FC with the sensorimotor network (SMN). Static thalamus–SMN FC was significantly higher in patients with high disability (EDSS ⩾ 4) and related to network atrophy but not thalamic atrophy or lesion volumes. Conclusion: The severity of disability in MS was related to increased static thalamic FC with the SMN. Thalamic FC changes were only related to cortical network atrophy, but not to thalamic atrophy.
KW - MRI
KW - Multiple sclerosis
KW - disability
KW - functional connectivity
KW - network
KW - thalamus
UR - http://www.scopus.com/inward/record.url?scp=85104771008&partnerID=8YFLogxK
U2 - https://doi.org/10.1177/13524585211008743
DO - https://doi.org/10.1177/13524585211008743
M3 - Article
VL - 28
SP - 61
EP - 70
JO - Multiple Sclerosis Journal
JF - Multiple Sclerosis Journal
SN - 1352-4585
IS - 1
ER -